titrating off zoloft B.1.351, and B.1.617.2. The sidechain interactions are denoted as SC. Credit: DOI: 10.1016/j.bbrc.2021.08.036″ width=”800″ height=”530″>
FIU researchers looking to unravel the secrets of how the coronavirus’ most contagious variant became so widespread have found an intriguing clue.
Computer modeling allowed researchers to see how mutations in a certain area of the delta variant may prevent antibodies from fully latching on to the virus. These antibodies—resulting from vaccination or from fighting a COVID-19 infection—help our immune system by interrupting or slowing the coronavirus at various steps in its process to invade a human cell and multiply.
The subtle structural changes could help explain why the delta variant is so contagious.
The discovery was made by a team of researchers led by Prem Chapagain, a physicist who is associate director of FIU’s Biomolecular Sciences Institute, and computer sciences professor Giri Narasimhan of the Knight Foundation School of Computing and Information Sciences in FIU’s College of Engineering and Computing. Their study was published in the journal Biochemical and Biophysical Research Communications.
“The delta variant seems to have found an immune escape,” Narasimhan said. “By mutating a little bit, it has weakened the impact of the antibody.”
Because the structural changes due to mutation occurred mostly in one region of the binding interface, there are still plenty of other parts of the virus where antibodies can latch on and prevent the virus from working as intended. It’s why vaccines are still effective against the virus.
“Viruses don’t make the changes knowingly,” Chapagain said. “Occasionally, they find something that will work better for them, and those variants will be more prevalent.”
Even the delta variant itself continues to mutate, which is why computer modeling efforts like those being undertaken at FIU could be the key to quickly understanding how future variants behave or stopping future pandemics in their tracks. The computational team led by Narasimhan is leveraging funding from the National Science Foundation to train computers that could one day predict how proteins from antibodies and viruses will interact.
Source: Read Full Article